Polus Solutions Pvt. Ltd. PolusSolutions
12th Floor, Carnival, Technopark Campus, Trivandrum 695581, Kerala Kazhakuttam , Thiruvananthapuram 695581
(425) 123-4567 [email protected]

Regen BioPharma

A user-centric website redesign case study in the biotechnology industry, spotlighting enhanced product showcase experience.

Project Overview

Regen BioPharma sought to revamp their online presence with a new website that highlights their breakthroughs in medical technology for cancer and autoimmune treatments. The goal was to create a visually appealing design that effortlessly communicates the company’s mission, product offerings, investor relations, and provides regular news and updates.

Client Profile

Regen BioPharma Inc., a publicly traded biotechnology firm, specializes in pioneering treatments utilizing autologous cell therapies, RNA and DNA-based immunotherapy, and small molecules within the immune-oncology and autoimmune disease domains. With a commitment to advancing cutting-edge technologies, the company is actively engaged in pre-clinical and Phase I/II clinical trials, focusing on modulating the immune checkpoint NR2F6 for cancer and autoimmune disorder treatments.

Our Solution

In response to Regen BioPharma’s requirements, Polus meticulously designed a user-friendly website. The product showcase was innovatively presented through a horizontal scroll, ensuring an engaging experience for visitors. Additionally, the website featured a dedicated section for the latest news and updates, enhancing the company’s transparency and communication with its audience. Integrated with a Google RSS news feed, visitors could stay updated with the latest developments in real-time. Furthermore, the website included a section for stock market updates, providing investors with crucial information. To facilitate efficient content management, WordPress was chosen as the Content Management System (CMS).

Technology Used

WordPress

let's make
great work
together

MENU

Resources

Learn how we helped 100 top brands gain success.

Let's have a chat